Changchun High-Tech Industry (Group) (000661) Q3 2026 earnings summary

Executive summary

• 9M 2026 revenue was ¥8.25B, down 15.86% YoY; net income attributable to shareholders was ¥586.1M, down 49.68%.

• Adjusted for non-recurring items, attributable net income was ¥687.2M, down 45.84%; operating cash flow rose 235% to ¥2.42B.

Financial highlights

• Q3 revenue was ¥2.71B, down 15.46% YoY; attributable net income was ¥110.8M, down 39.12%.

• 9M operating costs totaled ¥7.23B versus ¥8.20B YoY; selling expenses declined to ¥3.01B from ¥3.76B, while R&D expenses fell to ¥1.44B from ¥1.73B.

• 9M net income was ¥516.5M versus ¥1.06B YoY; attributable net income was ¥586.1M, with minority shareholders recording a ¥69.6M loss.

Segment performance

• Jin Sai Pharmaceutical 9M revenue was ¥6.68B, down 18.71% YoY; profit attributable to parent owners was ¥778M, down 45.26%.

• Baike Biotech revenue was ¥564M, up 18.84% YoY, with a ¥96M attributable loss; Huakang Pharmaceutical revenue declined 9.13% to ¥492M and attributable profit fell 10.47% to ¥32M.

• High-Tech Real Estate revenue rose 180.02% to ¥1.52B, with a ¥3M attributable loss; ¥1.042B from internal hotel-related asset restructuring was eliminated in consolidated results.